Correction to: Trials (2020) 21:391
https://doi.org/10.1186/s13063-020-04341-y
Following publication of the original article [1], the authors identified an error in Fig. 1, due to the change of the study protocol version (from 1.1 to 2.0). The following points in Fig. 1 need to be changed:
- The end of the registration period will be extended from April 2020 to December 2020.
- The duration of registration period will be changed from 33 to 41 months.
- The end of the follow-up period will be extended from April 2022 to December 2022.
- The end of the survival survey will be extended from October 2023 to June 2024.
The same changes apply to the text as well, as follows:
Trial Status section
- This study opened for recruitment in August 2017, with recruitment expected to be completed by December 2020. The first patient was enrolled in October 2017, and the actual number of patients recruited as of January 31, 2020 was 244.
- The current protocol is version 2.0 and was approved on November 5, 2019. Because of delayed registration, the registration and follow-up period for OS will be until December 2020 and June 2024., respectively.
Follow-up section
- All participants will be followed up until December 2022, i.e., 2 years after the last participant recruitment.
The correct Fig. 1 is presented below:
Study design flowchart
Reference
Yamashita T, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020;21:391. https://doi.org/10.1186/s13063-020-04341-y.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Yamashita, T., Masuda, N., Saji, S. et al. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials 21, 503 (2020). https://doi.org/10.1186/s13063-020-04408-w
Published:
DOI: https://doi.org/10.1186/s13063-020-04408-w